{
    "root": "3490033f-0c0c-bf3d-e063-6294a90a17da",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Phentermine Hydrochloride",
    "value": "20250507",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PHENTERMINE HYDROCHLORIDE",
            "code": "0K2I505OTV"
        }
    ],
    "indications": "phentermine hydrochloride capsules indicated short-term ( weeks ) adjunct regimen weight reduction based exercise , behavioral modification caloric restriction management exogenous obesity patients initial body mass index ≥ 30 kg/m 2 , ≥ 27 kg/m 2 presence risk factors ( e.g . , controlled hypertension , diabetes , hyperlipidemia ) . chart body mass index ( bmi ) based various heights weights . bmi calculated taking patient ’ weight , kilograms ( kg ) , divided patient ’ height , meters ( ) , squared . metric conversions follows : pounds ÷ 2.2 = kg ; inches x 0.0254 = meters . body mass index ( bmi ) , kg/m 2 limited usefulness agents class , including phentermine , [ se e pharmacology ( 12.1 , 12.2 ) ] measured possible risk factors inherent described .",
    "contraindications": "individualized obtain adequate response lowest effective dose . ( 2.1 ) late evening avoided ( risk insomnia ) . ( 2.1 ) phentermine hydrochloride capsules taken without food ( 2.1 ) limit 15 mg daily patients severe renal impairment ( egfr 15 29 ml/min/1.73m 2 ) - ( 2.2 )",
    "warningsAndPrecautions": "phentermine hydrochloride capsules usp , oral , available : 30 mg : blue/clear powder filled capsules ; imprinted “ n16 ” black ink supplied : ndc 72789-287-14 bottles 14 ndc 72789-287-28 bottles 28 ndc 72789-287-30 bottles 30 store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . protect moisture . dispense tight , light-resistant container defined usp , child-resistant closure ( required ) . keep reach children .",
    "adverseReactions": "• history cardiovascular disease ( e.g . , coronary artery disease , stroke , arrhythmias , congestive heart failure , uncontrolled hypertension ) • within 14 days following monoamine oxidase inhibitors • hyperthyroidism • glaucoma • agitated states • history abuse • pregnancy [ ( 8.1 ) ] • nursing [ ( 8.3 ) ] • known hypersensitivity , idiosyncrasy sympathomimetic amines",
    "indications_original": "Phentermine hydrochloride capsules are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m\n       \n \n  2, or ≥ 27 kg/m\n       \n \n  2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).\n      \n\n \n                  Below is a chart of body mass index (BMI) based on various heights and weights.\n                  BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.\n                  \n                     BODY MASS INDEX (BMI), kg/m\n                     \n                        2\n                     \n                  \n                  \n                  The limited usefulness of agents of this class, including phentermine, [se\n       \n \n  e \n                     CLINICAL PHARMACOLOGY (\n       \n \n  12.1\n                     , \n                     12.2)] should be measured against possible risk factors inherent in their use such as those described below.",
    "contraindications_original": "Dosage should be individualized to obtain an adequate response with the lowest effective dose. ( 2.1 ) Late evening administration should be avoided (risk of insomnia). ( 2.1 ) Phentermine hydrochloride capsules can be taken with or without food ( 2.1 ) Limit the dosage to 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73m 2 )- ( 2.2 )",
    "warningsAndPrecautions_original": "Phentermine hydrochloride capsules USP, for oral administration, are available as:\n                  \n                     30 mg:  Blue/Clear powder filled capsules; imprinted “N16” in black ink and supplied as:\n  \n                     \nNDC 72789-287-14 bottles of 14\n  \nNDC 72789-287-28 bottles of 28\n  \nNDC 72789-287-30 bottles of 30\n \n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  Protect from moisture.\n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).\n                  Keep out of the reach of children.",
    "adverseReactions_original": "• History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)\n       \n \n  • During or within 14 days following the administration of monoamine oxidase inhibitors\n       \n \n  • Hyperthyroidism\n       \n \n  • Glaucoma\n       \n \n  • Agitated states\n       \n \n  • History of drug abuse\n       \n \n  • Pregnancy [see \n       \n \n  USE IN SPECIFIC POPULATIONS (\n       \n \n  8.1)]\n       \n \n  • Nursing [see \n       \n \n  USE IN SPECIFIC POPULATIONS (\n       \n \n  8.3)]\n       \n \n  • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines"
}